Slide 1: FY22 Full Year Results Investor Presentation
NUCHEV LIMITED (ACN 163 225 090) LEVEL 10, 420 ST KILDA ROAD MELB 3004 WWW.NUCHEV.COM.AU ASX CODE: NUC 31 August 2022 ASX Market Release FY22 Full Year Results Investor Presentation Nuchev Limited (ASX:NUC) attaches the Presentation to be delivered to Investors during briefings on the Company’s 2022
Slide 2: Nuchev Limited FY22 Full Year Results
Nuchev Limited FY22 Full Year Results August 2022
Slide 3: Presenting Today / Agenda
PRESENTING TODAY AGENDA Nuchev’s purpose 2 FY22 impacts 3 Financial and business performance 4 Ben Dingle Key financial and operational metrics 5 CEO, Executive Director and Founder Strong fundamentals with capacity for growth 6 Strategically positioned for the future 7 Executing our strategy to dri
Slide 4: Our Purpose
OUR PURPOSE OUR PURPOSE FOOD FOR A BETTER LIFE We are committed to improving families’ lives DEMONSTRATED THOUGHT LEADERSHIP IN PREMIUM DIGESTION & IMMUNITY BY LEADERSHIP IN PREMIUM DIGESTION & IMMUNITY Backed by science Fuelled by consumer led innovation Backed by science World classby Fuelled ingr
Slide 5: FY22 Impacts
FY22 IMPACTS FY22 saw the Group progress whilst continuing to face challenges post COVID-19 with supply chain and demand impacted • CBEC market for infant formula reducing post double 11 2021 CHINA MARKET • Shift from local export to Corporate Daigou in B2C market CORRECTION • Continued disruption c
Slide 6: FY22 Financial & Business Performance
FY22 FINANCIAL & BUSINESS PERFORMANCE Volumes (Metric Tonnes1) Full Year Results Positive net cash position of $5.1m with no debt ▪ Through disciplined cost control measures and targeted sales initiatives, the Group was able to reduce its net cash consumed in operating activities by $1.2m Increased
Slide 7: Key Financial and Operational Metrics
KEY FINANCIAL AND OPERATIONAL METRICS Commentary FY22 FY21 % change ▪ Revenue and volume performance was down 11% and 10%, respectively due to the contraction in CBEC and continuing impacts of COVID-19 lockdowns, partially offset by Volume (MT) 1 332.6 370.2 (10%) growth in Australian retail channel
Slide 8: Strong Fundamentals with Capacity for Growth
STRONG FUNDAMENTALS WITH CAPACITY FOR GROWTH Nuchev Oli6® is a listed nutritional's platform with an experienced team and growth potential Core digestive and immunity infant Achievable growth potential and key Premium & Trusted Brand Company well positioned formula (IF) business is attractive risks
Slide 9: Strategically Positioned for the Future
STRATEGICALLY POSITIONED FOR THE FUTURE FUNCTIONAL FOODS & PRODUCTS FOR A BETTER LIFE 4. KEY STRATEGIC ATTRIBUTES Leading in premium digestion + immunity nutritional products 1. EXPANDING OUR PURPOSE ✓Health and wellbeing functional food & products promoting digestion & immunity 2. WHAT WE OBJECTIVE
Slide 10: Executing Our Strategy to Drive Scalable Growth
EXECUTING OUR STRATEGY TO DRIVE SCALABLE GROWTH PURPOSE FUNCTIONAL FOODS & PRODUCTS FOR A BETTER LIFE PRIMARILY FOCUSSED ON GOAT LEADING PREMIUM DIGESTION + PRODUCT MILK INFANT FORMULA IMMUNITY WELLNESS NUTRITIONALS POSITIONING SPECIALIST LEVERAGED & DIVERSIFIED IN INFANT FORMULA PLAYER FUNCTIONAL F
Slide 11: Appendix
APPENDIX
Slide 12: Group Profit & Loss Statement
GROUP PROFIT & LOSS STATEMENT $ millions Notes FY22 FY21 Notes Revenue 1 9.7 10.9 1. Revenue reflects the sale of GIF, other goat nutritional Cost of sales 2 (6.9) (7.4) products, and raw material ingredient sales. Gross Profit 2.8 3.5 2. Cost of sales include the total production costs for IF produ
Slide 13: Group Balance Sheet
GROUP BALANCE SHEET $ millions 30 June 2022 30 June 2021 COMMENTARY Cash and short term deposits 5.1 14.5 Trade and other receivables 1.6 1.1 • Cash reduced from $14.5m to $5.1m during the year, due a Prepayments 0.5 0.4 combination of investment and brand marketing Inventories 9.4 11.4 Other curren
Slide 14: Disclaimer
Disclaimer This presentation is provided by Nuchev Limited (ACN 163 225 090) (Nuchev) to provide summary information about Nuchev and its respective subsidiaries (together, the Group). Statements in this presentation are made as at the date of the presentation and the information in this presentatio
Slide 15: Slide 15